{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T01:28:15Z","timestamp":1778376495802,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T00:00:00Z","timestamp":1551052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s12020-019-01871-7","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T03:17:42Z","timestamp":1551064662000},"page":"605-613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2136-3866","authenticated-orcid":false,"given":"Inmaculada","family":"Peir\u00f3","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Palmero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreu","family":"Sim\u00f3-Servat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Antonio","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Domingo-Domenech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Mancho-Fora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest","family":"Nadal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Villabona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,25]]},"reference":[{"issue":"19","key":"1871_CR1","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, N. Minato, Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. 99(19), 12293\u20137 (2002). \n                    https:\/\/doi.org\/10.1073\/pnas.192461099","journal-title":"Proc. Natl Acad. Sci."},{"issue":"17","key":"1871_CR2","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"H. Borghaei, L. Paz-Ares, L. Horn, D.R. Spigel, M. Steins, N.E. Ready et al. Nivolumab versus Docetaxel in advanced nonsquamous non\u2013small-cell lung cancer. N. Engl. J. Med. 373(17), 1627\u201339 (2015)","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"1871_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"J. Brahmer, K.L. Reckamp, P. Baas, L. Crin\u00f2, W.E.E. Eberhardt, E. Poddubskaya et al. Nivolumab versus Docetaxel in advanced squamous-cell non\u2013small-cell lung cancer. N. Engl. J. Med. 373(2), 123\u201335 (2015). \n                    https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N. Engl. J. Med."},{"key":"1871_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejim.2017.08.019","volume":"47","author":"P Iglesias","year":"2018","unstructured":"P. Iglesias, Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach. Eur. J. Intern. Med. 47, 6\u201313 (2018)","journal-title":"Eur. J. Intern. Med."},{"issue":"19","key":"1871_CR5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"R.J. Motzer, B. Escudier, D.F. McDermott, S. George, H.J. Hammers, S. Srinivas et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373(19), 1803\u201313 (2015). \n                    https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"1871_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"C. Robert, G.V. Long, B. Brady, C. Dutriaux, M. Maio, L. Mortier et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372(4), 320\u201330 (2015). \n                    https:\/\/doi.org\/10.1056\/NEJMoa1412082","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"1871_CR7","doi-asserted-by":"publisher","first-page":"T331","DOI":"10.1530\/ERC-17-0358","volume":"24","author":"P Cukier","year":"2017","unstructured":"P.Cukier, F.C.Santini, M.Scaranti, A.O.Hoff, Endocrine side effects of cancer immunotherapy. Endocr. Relat. Cancer 24(12), T331\u201347 (2017)","journal-title":"Endocr. Relat. Cancer"},{"issue":"10","key":"1871_CR8","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","volume":"21","author":"JS Weber","year":"2016","unstructured":"J.S. Weber, M. Postow, C.D. Lao, D. Schadendorf, Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist 21(10), 1230\u20131240 (2016)","journal-title":"Oncologist"},{"issue":"2","key":"1871_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"R. Barroso-Sousa, W.T. Barry, A.C. Garrido-Castro, F.S. Hodi, L. Min, I.E. Krop et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens a systematic review and meta-analysis. JAMA Oncol. 4(2), 173\u201382 (2018)","journal-title":"JAMA Oncol."},{"issue":"4","key":"1871_CR10","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/cen.13297","volume":"86","author":"DL Morganstein","year":"2017","unstructured":"D.L. Morganstein, Z. Lai, L. Spain, S. Diem, D. Levine, C. Mace et al. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin. Endocrinol. 86(4), 614\u201320 (2017)","journal-title":"Clin. Endocrinol."},{"issue":"3","key":"1871_CR11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"J.C. Osorio, A. Ni, J.E. Chaft, R. Pollina, M.K. Kasler, D. Stephens et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann. Oncol. 28(3), 583\u2013589 (2017)","journal-title":"Ann. Oncol."},{"issue":"6","key":"1871_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40618-017-0778-8","volume":"41","author":"P Chalan","year":"2018","unstructured":"P. Chalan, G. Di Dalmazi, F. Pani, A.D. Remigis, A. Corsello, P. Caturegli, Thyroid dysfunctions secondary to cancer immunotherapy. J. Endocrinol. Invest. 41(6), 625\u201338 (2018)","journal-title":"J. Endocrinol. Invest."},{"issue":"3","key":"1871_CR13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2326-6066.CIR-17-0063","volume":"6","author":"A Lisberg","year":"2018","unstructured":"A. Lisberg, D.A. Tucker, J.W. Goldman, B. Wolf, J. Carroll, A. Hardy et al. Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center. Cancer Immunol. Res. 6(3), 288\u201394 (2018)","journal-title":"Cancer Immunol. Res."},{"issue":"14","key":"1871_CR14","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"P. Armand, A. Engert, A. Younes, M. Fanale, A. Santoro, P.L. Zinzani et al. Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkmate 205 trial. J. Clin. Oncol. 36(14), 1428\u201339 (2018)","journal-title":"J. Clin. Oncol."},{"key":"1871_CR15","unstructured":"V.K. Morris, M.E. Salem, L. Comprehensive, H. Nimeiri, S. Iqbal, L. Angeles et al. HHS Public Access. 2018;18(4):446\u201353"},{"issue":"9","key":"1871_CR16","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"M.J. Overman, R. McDermott, J.L. Leach, S. Lonardi, H.J. Lenz, M.A. Morse et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18(9), 1182\u201391 (2017)","journal-title":"Lancet Oncol."},{"key":"1871_CR17","doi-asserted-by":"publisher","unstructured":"S. Mancuso, M. Carlisi, M. Napolitano, S. Siragusa, Lymphomas and thyroid: bridging the gap. Hematol. Oncol. 2018:1\u20136. \n                    https:\/\/doi.org\/10.1002\/hon.2504","DOI":"10.1002\/hon.2504"},{"issue":"11","key":"1871_CR18","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1210\/jc.2016-2300","volume":"101","author":"J Filette De","year":"2016","unstructured":"J. De Filette, Y. Jansen, M. Schreuer, H. Everaert, B. Velkeniers, B. Neyns et al. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J. Clin. Endocrinol. Metab. 101(11), 4431\u20134439 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"1871_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1210\/js.2017-00432","volume":"2","author":"T Kobayashi","year":"2018","unstructured":"T. Kobayashi, S. Iwama, Y. Yasuda, N. Okada, T. Tsunekawa, T. Onoue et al. Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study. J. Endocr. Soc. 2(3), 241\u2013251 (2018)","journal-title":"J. Endocr. Soc."},{"issue":"12","key":"1871_CR20","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","volume":"5","author":"H Lee","year":"2017","unstructured":"H. Lee, F.S. Hodi, A. Giobbie-Hurder, P.A. Ott, E.I. Buchbinder, R. Haq et al. Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy. Cancer Immunol. Res. 5(12), 1133\u20131140 (2017)","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"1871_CR21","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1210\/jc.2014-4560","volume":"100","author":"S Orlov","year":"2015","unstructured":"S. Orlov, F. Salari, L. Kashat, P.G. Walfish, Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J. Clin. Endocrinol. Metab. 100(5), 1738\u201341 (2015)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"1871_CR22","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1089\/thy.2016.0562","volume":"27","author":"I Yamauchi","year":"2017","unstructured":"I. Yamauchi, Y. Sakane, Y. Fukuda, T. Fujii, D. Taura, M. Hirata et al. Clinical features of nivolumab-induced thyroiditis: a case series study. Thyroid 27(7), 894\u2013901 (2017)","journal-title":"Thyroid"},{"issue":"1","key":"1871_CR23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.gendis.2017.11.002","volume":"5","author":"TE Angell","year":"2018","unstructured":"T.E. Angell, L. Min, T.J. Wieczorek, F.S. Hodi, Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma. Genes Dis. 5(1), 46\u201348 (2018)","journal-title":"Genes Dis."},{"key":"1871_CR24","doi-asserted-by":"publisher","first-page":"JCO.2017.77.638","DOI":"10.1200\/JCO.2017.77.6385","volume":"4","author":"JR Brahmer","year":"2018","unstructured":"J.R. Brahmer, C. Lacchetti, B.J. Schneider, M.B. Atkins, K.J. Brassil, J.M. Caterino et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 4, JCO.2017.77.638 (2018). \n                    https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J. Clin. Oncol."},{"key":"1871_CR25","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"J.B.A.G. Haanen, F. Carbonnel, C. Robert, K.M. Kerr, S. Peters, J. Larkin et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann. Oncol. 28, iv119\u2013iv142 (2017). \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx225\n                    \n                  . suppl_4","journal-title":"Ann. Oncol."},{"issue":"1","key":"1871_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"I. Puzanov, A. Diab, K. Abdallah, C.O. Bingham, C. Brogdon, R. Dadu et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 5(1), 1\u201328 (2017)","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"1871_CR27","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2014-2306","volume":"99","author":"AT Faje","year":"2014","unstructured":"A.T. Faje, R. Sullivan, D. Lawrence, N.A. Tritos, R. Fadden, A. Klibanski et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J. Clin. Endocrinol. Metab. 99(11), 4078\u201385 (2014). \n                    https:\/\/doi.org\/10.1210\/jc.2014-2306","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1871_CR28","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.lungcan.2018.11.007","volume":"126","author":"K Sato","year":"2018","unstructured":"K. Sato, H. Akamatsu, E. Murakami, S. Sasaki, K. Kanai, A. Hayata et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 126, 230\u2013231 (2018)","journal-title":"Lung Cancer"},{"key":"1871_CR29","doi-asserted-by":"publisher","first-page":"b5087","DOI":"10.1136\/bmj.b5087","volume":"340","author":"EL Linda","year":"2010","unstructured":"E.L. Linda, A.H. James, S.S. Abbas Kezouh, Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. Br. Med. J. 340, b5087 (2010)","journal-title":"Br. Med. J."},{"issue":"4","key":"1871_CR30","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"S. Suissa, Immortal time bias in pharmacoepidemiology. Am. J. Epidemiol. 167(4), 492\u20139 (2008)","journal-title":"Am. J. Epidemiol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-019-01871-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-01871-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-01871-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T19:13:54Z","timestamp":1582571634000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-019-01871-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,25]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1871"],"URL":"https:\/\/doi.org\/10.1007\/s12020-019-01871-7","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,25]]},"assertion":[{"value":"8 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}